Podcasts about cancer care

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer. The conversation explores how social constructs and industry blame-shifting fuel psychological distress, create barriers to the National Lung Cancer Screening Program, and potentially compromise equitable patient care. The panel offers clinical, psychological, and biological perspectives on how the healthcare system can dismantle this stigma to improve patient outcomes and quality of life.  Host A/Prof Gavin Wright is a thoracic surgeon, director of Surgical Oncology at St. Vincent's Hospital, and the surgical representative on TOGA's scientific committee—is an esteemed panel of specialists leading the charge against lung cancer stigma. He is joined by Dr. Allison Black, an oncology consultant at the Royal Hobart Hospital who sub-specialises in gynecological and lung cancers; A/Prof Henry Marshall, a thoracic physician at the Prince Charles Hospital and the University of Queensland Thoracic Research Center; and Professor Suzanne Chambers, a health psychologist, psycho-oncology researcher, and Executive Dean of Health Sciences at the Australian Catholic University. Together, they bring a vital combination of surgical, oncological, respiratory, and psychological expertise to this crucial discussion.  00:00 Welcome and Acknowledgement 00:55 Meet the Panel 01:54 What Stigma Means 04:43 Tobacco Industry Blame 06:11 Why Screening Matters 08:44 Treatment Without Judgment 12:15 Fixing Stigma Systemwide 17:13 Equity and Access Gaps 18:35 Shared Decisions and Support 21:24 Quitting Without Shame 24:33 Language and Closing Takeaways 26:49 Episode Wrap Up ---------------Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

A prostate cancer diagnosis affects more than physical health. Learn how emotional support, evidence-based coping strategies, and community resources help patients and caregivers navigate treatment, recovery, and long-term well-being. For more information, visit https://prostaid.org/meetings/ Prostaid Calgary City: Calgary Address: 1600 90 Avenue Southwest Website: https://prostaid.org/

In this episode, Robert Stone, Chief Executive Officer, Helen and Morgan Chu Chief Executive Officer Distinguished Chair, City of Hope, discusses the organization's approach to expanding cancer care access, building philanthropic partnerships and keeping patients at the center of growth. He also shares his perspective on AI, technology and the future of cancer treatment.

For decades, cancer treatment has followed a familiar path. A tumor is found, surgery removes it, radiation burns what remains, and chemotherapy or immunotherapy attempts to destroy cells that may have spread elsewhere. These treatments have saved countless lives, yet they often come with immense physical, emotional, and financial costs. Many patients endure fatigue, pain, scarring, organ damage, mounting bills and lifelong side effects. However, the extraordinary advances of modern medicine have often included the commercial viability of a proven medical product, regardless of its cost and accessibility. The dream of a gentler, more precise, and more effective cancer treatment has remained elusive.

Attend the 2026 Testicular Cancer Conference: https://www.testicularcancerawarenessfoundation.org/tcc-indianapolis-2026When David Smith woke in the middle of the night with searing lower-back pain, he was two weeks out from the Beep Baseball World Series and in the best shape of his life. A legally blind wellness coach, nurse, and competitive adaptive-sports athlete, David assumed it was a kidney stone. Instead, an ER scan revealed a large mass near his kidney — and with no primary tumor found on ultrasound, doctors diagnosed him with testicular cancer at 41.In this episode of It Takes Balls, David shares one of the most powerful stories of self-advocacy the podcast has featured. Determined not to miss the World Series, he delayed treatment two weeks, then began BEP chemotherapy that quickly went sideways: a wiped-out immune system, terrifying bone pain from shots no one warned him about, and a blood clot in his lung. When bleomycin proved too dangerous, David — drawing on his own nursing knowledge and relentless research — pushed his oncology team to change his regimen himself.David doesn't hold back about the gaps in his care, from "factory"-like bedside manner to Googling his way to a nearby cancer center and an experienced surgeon he'd never been told about. His post-chemo RPLND removed 21 lymph nodes (all negative) but left him navigating a brutal recovery that nearly broke him.But this episode is really about what comes after. David opens up honestly about survivorship — the fear of recurrence, the identity crisis of remission, faith, and the ongoing work of figuring out who he really is. His message to anyone facing a diagnosis: advocate for yourself, do your research without letting it consume you, and hang tight — because far more people survive cancer than don't.Provide your feedback on the podcast:https://www.testicularcancerawarenessfoundation.org/itbsurveyJoin The Ball Room:https://www.testicularcancerawarenessfoundation.org/theballroomWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsConnect with David:https://www.instagram.com/dcsmith1006Follow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.x.com/testescancer⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker:https://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

Moving Cancer Upstream: Dr. Jose Barreau on Prevention, Prime Time, and the Fight to Detect Cancer Earlier Dr. Jose Barreau spent decades on the wrong side of a timeline every oncologist knows too well, treating cancer after it was found, often at a stage when the window for real intervention had already closed. That experience became the founding premise behind PreOncology, the company he built to move cancer care upstream from treatment to prevention. Barreau's work recently reached a much bigger audience. He's featured in The Chase: Inside the Race to Cure Cancer, a documentary now streaming on Amazon Prime Video that follows real patient experiences and the healthcare teams navigating one of life's hardest journeys. In this conversation, we talk about what it was like being part of that project, why the film's message about early detection lines up so closely with PreOncology's mission, and what he wants viewers to take away from it. We also get into the founding story behind PreOncology itself: why conventional screening was never built for the individual, why the technology to detect cancer earlier already exists but has never been properly integrated, and how an oncologist-led model is trying to close that gap. Barreau also shares lessons from his earlier work founding Doc Halo and Halo Health, healthcare communication platforms used by over 300,000 physicians nationwide. Dr. Barreau will be speaking live at the 2026 Concierge Medicine Forum this October in Atlanta, GA, where he'll go deeper into what personalized cancer surveillance actually looks like in practice. If this conversation resonates, that session is one worth planning your schedule around. Learn more about Dr. Barreau and PreOncology: https://preoncology.com/our-story/ Watch The Chase: Inside the Race to Cure Cancer on Amazon Prime Video. This episode is educational and informational. Nothing discussed should be considered medical advice.

Most clinician scientists face a brutal balancing act, but for Dr. Armen Parsyan, navigating the complex worlds of surgery and research has become his normal. How does one build a groundbreaking career across continents, disciplines, and institutions, even when systemic barriers seem insurmountable? Dr. Parsyan shares his astonishing journey from Armenia to Toronto, Cambridge, Boston, Montreal, and finally London, Ontario, a path filled with serendipity, relentless determination, and unyielding passion for innovation and patient care. In this episode, you'll discover how he managed to thrive despite limited institutional support, the critical role mentorship played in his success, and why resilience is the most vital traitfor emerging clinician scientists. Dr. Parsyan dives deep into the biggest challenges early career researchers face, funding constraints, bureaucratic roadblocks, and navigating dual clinical-research pathways, and offers pragmatic strategies for overcoming them. We break down thoughts on how toeffectively approach institutions pre- and post-hire, the importance of adaptability, and how to align your career goals with the funding landscape. His insights into how institutional rigidity hampers innovation and how to push past it are indispensable for anyone serious about making a mark in translational medicine.

  Failing to diagnose cancer means a doctor misses or delays finding the disease when clear warning signs exist  This error can let the cancer grow, leading to harder treatments and lower survival chances. Not every missed cancer is malpractice, but preventable delays may be.

In this episode, Dr. Harveshp Mogal and Dr. Michael O'Leary speak with Dr. Aditi Bhatt and Dr. Aaron Saunders about what it takes to build cytoreduction and HIPEC programs in settings where resources, infrastructure, and training pathways may be limited. Drawing on experiences from India and West Africa, the conversation explores how complex cancer care can be implemented sustainably through adaptation, partnership, and a long-term commitment to multidisciplinary excellence.

What would you do if you were told you might only have two years to live?In this inspiring and deeply practical episode of Linda's Corner Podcast, I sit down with Glenn Sturm — bestselling author, astrophotographer, attorney, decorated military officer, and cancer survivor — to discuss multidisciplinary cancer care, emotional resilience, and what it really takes to fight for joy and quality of life after a devastating diagnosis.Glenn's life story is extraordinary. A graduate with honors from the University of Florida Levin College of Law and a decorated military officer with more than three decades of service, Glenn built a remarkable career as both a lawyer and leader. But in 2009, his life changed overnight when doctors discovered he had aggressive T-cell lymphoma.The diagnosis came completely out of the blue. Glenn didn't even realize he had been screened for cancer. Doctors told him there was no cure — only management — and estimated he might survive for only two years.That was seventeen years ago.Since then, Glenn has endured continuous chemotherapy and more than 55 surgeries, yet he continues to live a meaningful and fulfilling life. His perspective is powerful and refreshingly honest. Glenn openly shares what people are rarely told about surviving cancer: how important it is to protect your energy, maintain emotional resilience, and intentionally pursue hope and joy.One of the central themes of our conversation is the importance of multidisciplinary cancer care. Glenn explains why creating a collaborative treatment team can dramatically improve outcomes for cancer patients. He shared research suggesting that multidisciplinary approaches may reduce mortality rates anywhere from 14% to 90% compared to isolated or solo treatment strategies. His upcoming book, More Than Hope, explores these integrated cancer care approaches in greater depth.We also discuss the importance of quality of life during treatment. Glenn shares how finding the right medication dramatically improved his energy levels, which in turn improved both his daily life and longevity. As Glenn explains, improving quality of life is not just about comfort — it can also help people live longer. A true win-win.Beyond medicine, Glenn speaks candidly about the emotional side of survivorship and the daily decision to keep moving forward. His message is grounded in practical emotional survival and the belief that while we cannot control every circumstance, we can choose how we respond. As Glenn says, “Only you can stop you.”This episode is a powerful reminder that hope is not passive. It's something we actively build through connection, resilience, strategy, and purpose.You can learn more about Glenn Sturm and his work at:Glenn Sturm Official WebsiteGlenn is the author of several bestselling books, including:Cancer Set Me FreeWarriors Hate WarSyzygiesThe Great American Eclipse of 2017More Than Hope (upcoming)If you or someone you love has been impacted by cancer, chronic illness, or difficult life challenges, this episode offers practical wisdom, encouragement, and a hopeful reminder that life can still hold meaning, joy, and purpose — even in the middle of hardship.Listen, Share, and SupportIf this episode resonated with you, please share it with someone who may need hope today.Be sure to subscribe, leave a rating and review, and help us spread more healing and inspiration to the world.Free Resource for HealingIf you're ready to release stress, calm your mind, and begin healing from within, visit:

In this episode, Dr. James McGee, Osf Healthcare Cancer Institute, discusses the urgent need to expand cancer prevention and early detection in rural communities while addressing the unique challenges rural providers face. He also shares his perspective on AI in oncology, the growing impact of obesity on cancer care, and emerging innovations that could improve access and reduce the cost of treatment.

"When people with PTSD [post-traumatic stress disorder] get quite avoidant—and that can be expressed in so many different ways—the implications can be really profound. I think an important invitation to oncologists and oncology nurses and primary care providers who care for people battling cancer is let's explore what's underneath these avoidant behaviors. Is it a very practical thing? Or is it that underneath this avoidant behavior is really profound fear?" James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about addressing medical trauma in oncology. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 31, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to medical trauma in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 421: Medical Trauma in Oncology Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Episode 264: Stop the Stressors and Improve Your Mental Health as a Nurse ONS Voice articles: Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD [post-traumatic stress disorder] Past Trauma Lowers Hope, QOL, and Coping Ability During Cancer Managing Cancer-Related PTSD Starts With Acknowledgement Moral Injury and Trauma in Nursing Trauma-Informed Care Provides Person-Centered Support for Patients During Deep Distress Clinical Journal of Oncology Nursing articles: How Can a Trauma-Informed Care Approach Be Applied to Patients With Gynecologic Cancer? Psychosocial Barriers to Care: Recognizing and Responding Through a Trauma-Informed Care Approach Oncology Nursing Forum articles: Post-Traumatic Distress and Symptom Experience in Patients With Head and Neck Cancer–Related Tracheostomy and Family Caregivers The Effect of Neuroticism, Fear of Progression, and Self-Efficacy on Post-Traumatic Growth in Patients With Lung Cancer Undergoing Chemotherapy The Relationship Between Colorectal Cancer Survivors' Positive Psychology, Symptom Characteristics, and Prior Trauma During Acute Cancer Survivorship ONS course: Psychosocial Dimensions of Cancer Care™ ONS Huddle Card: Coping Screening tools Clinician-Administered PTSD Scale for DSM-5 [Diagnostic and Statistical Manual of Mental Disorders, 5th edition] (CAPS-5) Hospital Anxiety and Depression Scale Primary Care PTSD Screen for DSM-5 PTSD Checklist for DSM-5 Trauma Screening Questionnaire International Society for Traumatic Stress Studies: Free Resources PESI Reclaiming Your Life From Medical Trauma by James C. Jackson To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "For many people who have been traumatized, if they can avoid it, they will. They may not avoid the annual evaluation that is so hugely consequential—they might not avoid that. But they may well avoid a routine visit for a checkup to their oncologist. They very well may avoid a visit with a psychologist who is wanting them to talk about hard things. They may avoid visiting a friend in the hospital because it reminds them of really upsetting things. So, this issue of adherence and compliance is a really big problem." TS 3:19 "Screening tools for things like PTSD can be very useful. They're quite practical, and they're appropriate to use. I really like something called the Post-Traumatic Stress Disorder Checklist. ... Using it is going to be very straightforward. You're going to want to map it onto a 30-day window, and you're going to employ it with patients. It's a 20-item self-report. It assesses 20 DSM-5 symptoms of PTSD. It's not diagnostic, but if people score in this range of 30, 31, 33, we typically are going to believe that that is very suggestive of significant PTSD." TS 9:17 "One of the things we should be doing all the time is modeling and attempting to normalize this idea of being open about mental health difficulties. When I say modeling, this is a complicated issue. ... I'm very open talking about my own battles with mental health. And in some ways, that invites my patients to do the same. I don't recommend necessarily that a nurse says, 'Oh, by the way, I have PTSD. I'm going to tell you about mine. I want you to tell me about yours.' That's a boundary issue. But I think it does behoove us as clinicians to create a culture as much as we're able, where we can talk about mental health difficulties in a matter-of-fact way, acknowledging that mental health is health. These tools, to me, go a long way in that direction." TS 13:41 "The survivorship process is ongoing. I think a nurse can assist a patient in so many ways longitudinally over time. ... One of those ways is to continue checking on mental health outcomes in patients. Continuing to check on mental health outcomes, continuing to explore them, and continuing to invite patients to talk about things that other people might not be asking about. It's easy for family members to assume, 'Hey, you know, you're cancer free now. You look fine, so you must be fine.' It's very possible that the patients we're talking about are not fine. They're far from fine. For that oncology nurse at a follow-up clinic or in an oncology setting to talk about this, continuing to affirm that it would be okay for patients to struggle, continuing to put this issue on a front burner—I think that's really important." TS 21:17 "I'm aware of nurse-led support groups where nurses can talk very freely about their own challenges, in a safe space. ... Working to build cultures in the context of the intensive care unit, let's say, where we have a lot of patients with cancer that prioritize well-being nurse driven programs. ...  The bottom line is if there is a warning light that is blinking, nurses need to attend to that. And in attending to it, they're going to be more present for their patient. They're going to be better able to support their patient. They're going to be better able to support each other. And I think often, in the culture of nursing and psychology, too, people just put their head down, their shoulder down, and they just plow through in ways that are really counter to their mental health." TS 29:56 "The truth is medical trauma can be well-managed. It's not simple. It's not always intuitive. There are all sorts of caveats with regard to this, but the truth is people with medical trauma can live really rich and meaningful lives. ... So, the default setting, I think, should be not one of pessimism. It should be that people with medical trauma can and do get better. If you are a patient with medical trauma and you are in my purview, until proven differently, I'm going to assume that you can get better too." TS 36:28

In this episode, David Debono, MD, Oncology Medical Director at Carelon Health, shares how technology, clinical pathways, and data-driven insights are helping improve cancer care while supporting physicians, expanding access, and delivering more personalized treatment for patients.

In this episode of Oncology Unscripted, hosts Mark Liu and Deirdre Saulet speak with Arif Kamal, MD, Chief Patient Officer at the American Cancer Society (ACS). Dr. Kamal discusses his recent appointment to this inaugural role at ACS, leading into a conversation about how he expects the cancer care field to evolve. Namely, a shift for providers toward building a skillset for compassionate patient conversations, a shift toward self-administered treatment modalities whenever possible, and new payment models for multi-cancer early detection tests. Dr. Kamal also shares how ACS's recently launched Access to Clinical Trials and Support program—an education-forward initiative designed is helping to reduce the challenges and barriers patients face when enrolling in clinical trials. "When you think about...the goal of cancer care...it's about more and better days. It is a false choice to choose between one or the other...As we're getting people to the other side [of treatment], are we leaving them financially devastated, significantly lonely, without support around them?" – Arif Kamal, MD Arif Kamal, MD Chief Patient Officer American Cancer Society To submit a topic of discussion to the podcast, please email mark.liu@mountsinai.org and deirdre.saulet@hellojasper.com. The 2026 Oncology Unscripted series is exclusively sponsored by Advarra. Resources Spirituality and Cultural Humility: Core Components of Comprehensive Palliative Care Together As One: Advancing Joy, Resilience, and Peer Support in Oncology Care Oncology Unscripted: Transforming Palliative Care in Oncology

In this episode, David Debono, MD, Oncology Medical Director at Carelon Health, shares how technology, clinical pathways, and data-driven insights are helping improve cancer care while supporting physicians, expanding access, and delivering more personalized treatment for patients.

Discover the Power of Herbal Medicine in Cancer Care with Petra SovcovJoin host Ivelisse Page on the Believe Big podcast as she welcomes Petra Sovcov, a clinical herbal therapist and Doctor of Natural Medicine based in Vancouver, BC. Founder of Healing House Natural Wellness, Petra brings decades of experience helping patients with chronic inflammatory conditions, including cancer and autoimmune diseases. In this enlightening episode, Petra shares practical, science-backed insights on how herbal remedies can complement conventional care to support detoxification, emotional health, and mental clarity.Petra discusses:Why it's vital to slow down and make informed decisions in a health crisisHow to source high-quality herbs and read product labels wiselyWhich herbs are most effective for detox and emotional balanceHow herbal tinctures can enhance treatment outcomesWhether you're a patient, caregiver, or health advocate, this episode is full of actionable tips to naturally strengthen your healing journey. Learn more about Petra Sovcov at Healing House Natural WellnessSuggested Resource Links:Petra's BlogInstitute of Holistic Nutrition - onlineWild Rose College of Herbal MedicineHerbalists Without BordersBC Herbalist AssociationCanadian Council of Herbalist AssociationsAmerican Herbalist GuildAmerican Herbal PharmacopiaYour donations power our podcast's mission to support cancer patients with hope, insights, and resources. Every contribution fuels our ability to uplift and empower. Join us in making a lasting impact. Donate now!

Should you go natural or conventional? Dr. Pai explains how to combine treatments based on labs, cancer type, and risk—plus avoid unnecessary therapies. #IntegrativeOncology #CancerCare #SmartMedicine

In this episode, Frantz M. Berthaud, MPH, FACHE, Senior Vice President, Oncology Services, University Medical Center of El Paso (UMC), discusses why cancer care leaders should measure both return on investment and return on humanity. He also shares insights on expanding oncology capacity, advancing health equity, and building a workforce and culture centered on compassionate, patient-focused care.

Good Vibe Tribe - DoMor For Cancer Care Gala full 300 Fri, 24 Jul 2026 12:14:07 +0000 9TKnZk5tZxuIJAzkTUDEKC57u6NpqDDl latest,wbmx,society & culture Karson & Kennedy latest,wbmx,society & culture Good Vibe Tribe - DoMor For Cancer Care Gala Karson & Kennedy are honest and open about the most intimate details of their personal lives. The show is fast paced and will have you laughing until it hurts one minute and then wiping tears away from your eyes the next. Some of K&K’s most popular features are Can’t Beat Kennedy, What Did Barrett Say, and The Dirty on the 30! 2024 © 2021 Audacy, Inc. Society & Culture https://player.amperwavepodcasting.com?feed-link=h

Debra Patt, MD, PhD, MBA, discusses how electronic monitoring is reducing administrative burden for oncology clinicians.

In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including: The evolving role of chemotherapy Utility of tumor treating fields for the treatment of locally advanced pancreatic adenocarcinoma Emerging RAS-targeted strategies and novel approaches for CLDN18.2- and MTAP-altered disease The potential impact of these developments on future treatment sequencing and supportive care  Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Paul E. Oberstein, MD, MS Section Chief, GI Oncology Associate Professor of Medicine Co-Director, KRAS Excellence Initiative Perlmutter Cancer Center NYU Langone Health New York, New York Andrew H. Ko, MD, FASCO Professor of Medicine and Associate Chief Division of Hematology/Oncology University of California San Francisco San Francisco, California Efrat Dotan, MD, MTR Clinical Professor of Medicine (Hematology/Oncology) Executive Medical Director, Penn Medicine, Ann B. Barshinger Cancer Center Penn Center for Cancer Care Innovation, Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Link to full program: https://bit.ly/44HPR1U Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On this episode host Justin Barnes returns to the Moffitt Cancer Center for this first of a 7-part series for a deeper dive into oncology of today. Part 1, Digital Innovation & the Future of Cancer Care with Kamal Jethwani, MD, VP Digital Ventures & CEO AccelerOnc and Nainesh Parikh, MD, VP Chief Expansion & Partner Officer from the Center. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

What if the milk you are drinking could help fight cancer? In this episode of Tomorrow's Cure, we explore cholangiocarcinoma and a surprising new approach to targeting it using milk‑derived nanoparticles and precision aptamer‑based delivery. Host Lindsey Seavert is joined by surgical oncologist Dr. Rory Smoot and long‑term survivor and advocate Melinda Bachini to unpack why this cancer is so challenging, what symptoms and treatment paths patients typically face, and how emerging gene‑delivery platforms and AI‑driven discovery are opening new possibilities when standard therapies fall short. Through Melinda's 16‑year survivorship story and Dr. Smoot's lab work that literally starts with skim milk from the Mayo Clinic cafeteria, listeners hear how “chemical antibodies” called aptamers can act as molecular keys to deliver therapy directly to cholangiocarcinoma cells, and how computational tools are accelerating the search for new targets. Together, they discuss the emotional and practical realities of living at the edge of what medicine can do today, the expanding landscape of clinical trials, and why innovation in this rare cancer may ripple out to colon, lung and other hard‑to‑treat tumors. How to listen and stay connected: Subscribe to Tomorrow's Cure on your favorite podcast app and follow the show so you never miss an episode. Get the latest health information from Mayo Clinic's experts—subscribe to Mayo Clinic's newsletter for free today: https://mayocl.in/3EcNPNc Connect with Mayo Clinic: Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/ Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/ Follow Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinic Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic

July 14, 2026 | Most ADCs today lean on the same Topo-1 payloads—and resistance is catching up. Jack Elands, Ph.D., founder and CEO of Adcytherix, speaks with host Rakesh Dixit, Ph.D. about what “next-generation ADCs” should mean if we care about patients, not just pipeline counts. Their conversation gets specific about where differentiation comes from: novel payloads with new mechanisms of action, better therapeutic index choices, and smarter design decisions that reduce the toxicities that make patients quit therapy early. They also pressure-test the hype around bispecific ADCs and dual-payload ADCs.  Links from this episode:  Adcytherix 

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. Although many GISTs can be effectively treated with targeted therapies, their response to treatment depends largely on the specific genetic alterations driving tumor growth. Advances in molecular testing have transformed the management of these tumors, allowing clinicians to tailor treatment based on each patient's genetic profile. A case report published in Volume 17 of Oncotarget, titled “Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report,” describes an exceptionally rare case involving a patient whose tumor carried two genetic alterations that are traditionally considered mutually exclusive. Full blog post - https://www.oncotarget.org/2026/07/13/rare-genetic-combination-in-gastrointestinal-tumor-offers-new-insights-into-precision-cancer-care/ DOI - https://doi.org/10.18632/oncotarget.28863 Correspondence to - Joseph G. Crompton - jcrompton@mednet.ucla.edu Abstract video - https://www.youtube.com/watch?v=eB_QG2vBNCE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28863 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, GIST, KIT duplication, SDHC mutation, genetic testing, case report To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show

Experts discuss diagnosing and treating insomnia in patients with cancer through methods like sleep hygiene, CBT-I, and pharmacotherapy.Insomnia is one of the most common symptoms oncologists are asked to manage, yet it's often treated reactively with medication rather than through a structured, history-driven approach. In this episode of Oncology On the Go, Daniel C. McFarland, DO, sat down with psychiatrist and psycho-oncologist Virginia C. O'Brien, MD, to unpack how clinicians can more effectively evaluate and treat insomnia in patients with cancer.The conversation opened with a foundational distinction: primary vs secondary insomnia, and why secondary insomnia—driven by anxiety, depression, pain, or cancer treatment itself—is far more common in oncology populations. O'Brien emphasized that the most frequent clinical mistake is jumping straight to a prescription instead of taking a thorough sleep history, including which phase of sleep is disrupted (falling asleep, staying asleep, or early waking) and whether the problem is affecting daytime functioning.From there, the discussion moved through practical sleep hygiene strategies clinicians can share with patients, such as limiting caffeine and screens, managing pets and partners in the bedroom, and setting a consistent nighttime routine. Then, they dove into cognitive behavioral therapy for insomnia (CBT-I), the first-line recommended treatment. O'Brien explained how sleep restriction works, why it's often impractical during active chemotherapy, and how free digital tools like CBT-i Coach can help fill access gaps.The latter part of the discussion tackled pharmacologic management in detail: when medications are appropriate for acute insomnia; how to sequence options from least to most habit-forming; and specific guidance on trazodone (Desyrel), ramelteon (Rozerem), zolpidem (Ambien; including FDA dosing warnings for women), benzodiazepines, and newer orexin receptor antagonists. Special attention was given to older patients, those with a fall risk, and patients with a history of substance use disorder.The experts closed with guidance on when to refer to a sleep medicine specialist, including STOP-BANG screening for obstructive sleep apnea and red flags for parasomnias like REM sleep behavior disorder.McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being a psycho-oncology editorial advisory board member for the journal ONCOLOGY®. O'Brien is system director of Ambulatory Psychiatry at the Carilion Clinic. 

In this episode, Dr. Robert Figlin, Cedars-Sinai Cancer Institute, discusses improving patient access to specialized cancer care, expanding clinical trial opportunities, and using AI to streamline care delivery. He also shares why advances in research and innovation are giving oncology leaders more reason for optimism than ever before.

Eric Lefkofsky, Founder and CEO of Tempus AI, joins Dr. Sanjay Juneja and Dr. Doug Flora to explore how artificial intelligence, real-world data, genomic sequencing, and emerging technologies like organoids are reshaping oncology. From reducing diagnostic errors to matching patients with more effective therapies, AI is transforming how clinicians make decisions and how researchers develop the next generation of treatments. The conversation examines why healthcare adoption has lagged behind technological progress, the growing role of patient-driven intelligence, and how connected data may help eliminate thousands of preventable cancer deaths each year. Eric also shares his vision for AI-powered clinical decision support, digital twins, drug development, and the future relationship between physicians and intelligent systems.

In this episode, Richard Barakat, MD, Physician-in-chief & Executive Director at Northwell Health Cancer Institute, discusses expanding access to advanced cancer therapies, integrating AI into oncology care, and driving the future of precision medicine. He also shares insights on improving efficiency, survivorship care, and clinical trial access for all patients.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Dr. Ashwin Singh Parihar sits down with Dr. Louise Emmett to discuss how post-therapy Lutetium-177 PSMA SPECT/CT may help predict overall survival in patients with metastatic castration resistant prostate cancer and shape future treatment decisions. Drawing from the ENZA-p trial run by ANZUP cancer trials group, they explore quantitative imaging, treatment response assessment, adaptive dosing strategies, and the growing role of theranostics in precision oncology.   177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Ayati et al. Radiology 2026; 319(1):e252672.

As cancer incidences continue to rise across the country. The Presidents of Ireland's cancer care representative bodies, along with the Irish Cancer Society, are warning that key parts of the care system are struggling to keep pace. Speaking to Anton was Dr Michael McCarthy the President of the Irish Society for Medical Oncology and is a signatory on the joint letter.

Send us Fan MailFor decades, cancer treatment has rested on three pillars: surgery, chemotherapy, and external beam radiation. A fourth is now taking shape, and it is drawing billions in investment from some of the largest pharmaceutical companies in the world.John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, joins host David E. Williams to explain how targeted radiotherapeutics pair a tumor-seeking molecule with a radioactive payload, delivering radiation to cancer cells while sparing healthy tissue. He also unpacks what Pluvicto's success in prostate cancer signals for the future of radioligand therapy.

Fifteen years after her cancer diagnosis, Sheila Dillon asks what role food could play in cancer treatment, prevention and recovery - and why it is still so often overlooked.Earlier this year, the Government published a new 10-year National Cancer Plan for England, aiming to save 320,000 lives and ensure three in four people survive at least five years after diagnosis by 2035. It's been welcomed as an ambitious strategy, yet some say it has little to say about diet. References to food focus largely on reducing obesity - by making supermarkets to monitor and report on sales of healthy and unhealthy foods, and expanding access to weight-loss drugs. It also includes commitments to improving hospital food for children with cancer, and introducing prehabilitation programmes via the NHS App by 2028. So where does that leave food itself - in treatment, in recovery, and in the risk of relapse?Featuring interviews with: Clare Doney, the clinical lead for personalised care for the Northern Cancer Alliance covering the North East and North Cumbria. Dr Giota Mitrou, Executive Director of Research and Policy at World Cancer Research Fund International Prof. Robert Thomas, head of oncology at the Royal London Hospital for Integrated Medicine, part of University College Hospital and consultant oncologist at Addenbrooks hospital in Cambridge.Produced by Natalie Donovan for BBC Audio in BristolResources:https://mywellbeingspacenca.nhs.uk/https://www.wcrf.org/living-well/living-with-cancer/cancer-and-nutrition-helpline/These links will take you to an external website. The BBC is not responsible for the content of external sites.

"There are a huge array of medical dynamics that people endure, and when they leave a lasting impact, a word that we don't use widely enough is the word 'trauma.' There's an entire category of phenomena in the medical arena that are, in fact, traumatic. One way we know that these experiences are traumatic is that we know that huge portions of people who experience things like cancer do indeed develop problems like [post-traumatic stress disorder]," James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about understanding medical trauma in oncology. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 26, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge of medical trauma and its effects on patients with cancer, caregivers, and healthcare professionals. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 315: Processing Grief as an Oncology Nurse Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Episode 276: Support Young Families During a Parent's Cancer Journey Episode 257: Redefining the Bell: The Ethics of Hope for Oncology Nurses and Patients Episode 103: What Oncology Nurses Need to Know to Support Caregivers ONS Voice articles: 'Between Two Kingdoms' Gives Us a Glimpse Into How Patients and Families Experience Malignancy AYA Cancer Survivors Experience Five Times Higher Depression Rates Than Individuals Diagnosed at Older Ages From Stigma to Support: Changing the Cancer Conversation Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD Moral Injury and Trauma in Nursing Trauma-Informed Care Provides Person-Centered Support for Patients During Deep Distress When the Story Ends, Cancer Does Not Win: Reframing Death in Terminal Cancer Care Word Choice Matters When Caring for Patients With Cancer ONS course: ONS Psychosocial Dimensions of Cancer Care™  Clinical Journal of Oncology Nursing articles: Psychosocial Barriers to Care: Recognizing and Responding Through a Trauma-Informed Care Approach Trauma-Informed Care Addressing the Mental and Emotional Needs of Patients With Cancer Oncology Nursing Forum articles: Post-Traumatic Distress and Symptom Experience in Patients With Head and Neck Cancer–Related Tracheostomy and Family Caregivers The Effect of Neuroticism, Fear of Progression, and Self-Efficacy on Post-Traumatic Growth in Patients With Lung Cancer Undergoing Chemotherapy Reclaiming Your Life From Medical Trauma by James C. Jackson To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Many people have a notion about what medical trauma is, but perhaps they lack a definition. I use a definition that is deliberately broad because I think it is better to be inclusive than exclusive. A medical trauma to me is a medical experience or a medical encounter that basically leaves a mark. It leaves an emotional mark, and that mark is significant enough to disrupt your daily life." TS 2:06 "When somebody develops a life-threatening illness—let's say cancer—it's not their problem only. It's very much a family problem. It affects any manner of people. There is literature that says that family members of people with life-threatening conditions often have rates of PTSD that are every bit as high as the patients do. There's also literature that says that if we can identify this issue as a family problem—a family challenge, not just an individual challenge—then very often that patient is going to do better." TS 8:23 "We just need to make space for people to feel however they feel. And we need to emphasize, I think, that in some ways, even though there's no cancer on the scan, cancer casts a long shadow in the lives of people, which is why when patients after cancer see their primary care provider, when they come back for a checkup with oncology, we need to continue this conversation of 'How is your mental health? Are you okay? How's your anxiety? How are you managing?' … We need to be really curious and kind, and we need to query people about how they're doing, even if officially they don't have cancer." TS 16:20 "Trauma-informed care has become a bit of a buzzword in our culture. But when it is engaged correctly, I think it's really important. And I think in a nutshell, what it means is that as providers, we need to recognize that some situations and circumstances are likely to be traumatic, and we need to pivot and engage people differently now that we know that. Specific features of trauma-informed care might be we're really going to value your emotional safety. We're going to emphasize that. We are going to emphasize boundaries. We are going to ask your permission instead of telling you how to do things. We are going to be really attentive to the language we use to engage you because we're aware of there might be things about your situation that are really triggering." TS 28:15 "I think one [misconception] certainly is that it is only afflicting and affecting people who are frail or weak—not very strong. That's emphatically not true. But that's a popular misconception—that if I'm strong enough, if I'm resilient enough, this experience will not be traumatic to me. It's just not true. Medical trauma doesn't just happen in emotionally weak people. Medical trauma can impact people of all sorts." TS 33:42 "The other misconception, I think, is that there is no hope for people in the throes of medical trauma. I'm not advocating 'hopium,' It's a term that was coined, I think, during the pandemic. I don't think that living with medical trauma is all rainbows and unicorns and shiny things. But the truth is, if you get the treatment that you need, you can find a way to thrive with medical trauma even as you're impacted by medical trauma. This, this 'both-and-ness' is really true. You can both be adversely affected and you can even find some beauty in your struggle. Both can be true." TS 34:13 "I wish people understood that there is a name for this phenomenon. We're naming it here today medical trauma. Not everyone who has cancer has medical trauma—not even close—but there are many people who do. And I think many of those people, they don't quite have a name for it. And when I introduce this name for it—trauma—many of them say, 'Oh, my gosh, that makes so much sense. I didn't quite understand why I was struggling so much with this. I didn't quite understand why it casts such a long shadow in my life. I didn't really understand why I was having panic attacks every time I had to get another scan at the oncology office to see if my breast cancer had returned. Now I understand. Now I understand it's because it was trauma.'" TS 35:09

What does it actually look like when a doctor refuses to give up on a patient, even when the statistics say there's nothing left to do?In this episode of Integrative Cancer Solutions, Dr. K sits down with Dr. William Nelson, NMD, a naturopathic oncologist with nearly 30 years in practice, to walk through the tools and thinking behind some of his most remarkable patient outcomes. From a stage 4 colon cancer case with an inoperable tumor and mets to the liver and lung who now has no evidence of disease, to the science behind mistletoe fever induction and regional hyperthermia, this conversation goes deep into what integrative cancer care can do when it's done right. Dr. Nelson also breaks down the real difference between naturopathic medicine and functional medicine, why chemotherapy alone can never finish the job, and how he uses mistletoe not as a replacement for conventional care but as the immune reset that makes everything else work better.If you or someone you love is navigating a cancer diagnosis and wondering whether there's more to the picture than surgery, chemo, and radiation, this episode is worth your full attention.Key Takeaways:0:00 Introduction1:12 Naturopathic oncology treats the whole patient not just the tumor6:06 Naturopathic medicine vs functional medicine10:07 Why more supplements is not better in cancer care13:00 Patients hiding integrative care from their oncologist15:46 Stage 4 colon cancer with no evidence of disease19:04 Mistletoe fever induction for advanced cancer25:07 Hyperthermia delivers 1500% more chemo without more toxicity29:44 Mistletoe as immune modulator not just cancer killer33:11 How mistletoe teaches the immune system to recognize cancer36:22 Mistletoe used safely alongside immunotherapy38:48 Believe Big offers financial support for mistletoe treatment Schedule a Free 15-Min Cancer/Lyme Consultation at The Karlfeldt Center: 208-338-8902Resources:Believe Big — https://www.believebig.orgJohns Hopkins Medicine — https://www.hopkinsmedicine.org Medical Disclaimer: This content is for educational purposes only and is not intended to diagnose, treat, cure, or replace professional medical advice. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions.

This episode explores why carbon ion therapy is becoming one of the most closely watched developments in radiation oncology. The conversation should connect patient need, the engineering scale behind heavy particle therapy, and the larger research questions now shaping how carbon ions may fit alongside photon and proton therapy in the future. How to listen and stay connected: Subscribe to Tomorrow's Cure on your favorite podcast app and follow the show so you never miss an episode. Get the latest health information from Mayo Clinic's experts—subscribe to Mayo Clinic's newsletter for free today: https://mayocl.in/3EcNPNc Connect with Mayo Clinic: Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/ Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/ Follow Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinic Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic

Truth Be Told with Booker Scott – Cancer care needs truth, transparency, and real patient choice. Families question a system that often rushes toward chemo, radiation, and surgery while overlooking nutrition, prevention, and natural approaches. Operation World Without Cancer highlights the demand for honest debate, integrative care, and freedom to pursue every path toward health and healing...

Music is more than entertainment — it's a form of healing. In this episode of the miniVHAN podcast, PJ Cowan, senior program manager of the nonprofit Musicians On Call, shares how they are transforming patient care through live music, emotional connection and whole-person care.

In this inspiring episode, Dani is joined by two breast care clinical nurse specialists from Milton Keynes University Hospital NHS Foundation Trust to explore what's possible when healthcare professionals truly listen, learn and work together to improve menopause care for women after cancer treatment.If you're a patient, this is a must-listen so that you can set realistic expectations of what's possible. If you're a healthcare professional, you'll be blown away by what Jaqcui and her team have achieved through hard work and persistence.Clinical Nurse Specialist Jacqui shares how she helped shape and evolve the support offered within her team around menopause after cancer, bringing colleagues together, opening up important conversations, and helping create more compassionate, informed care for patients navigating life after treatment. She is joined by her colleague, Christina for an honest discussion about what they've learned from patients over the years, the gaps they began to recognise, and the practical changes that can happen even within stretched NHS services and limited resources.Dani says, “Thank you for being utterly amazing!”Jaqcui and Christina mention Dani's book and say how helpful it is for them. You can buy a copy here: https://amzn.eu/d/04P0N9FXAnd here is www.menopauseandcancer.org for more information and support.Episode Highlights:00:00 Intro08:06 Addressing menopause post-cancer treatment14:24 Learning from patient engagement17:06 New prescribing practices in oncology20:25 Discussing Tamoxifen Prescription Options26:16 Discussing hormone therapy side effects27:46 Discussing bone health in menopause36:37 Challenges in patient care response37:53 Menopause care post-cancer42:44 Focusing on menopause and cancer43:52 Planning patient support events49:11 Empowering patient-doctor conversationsConnect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub

What if some of the most promising discoveries in cancer research were hidden from public view?  Discover how plant-based compounds may help support healthy cells and why addressing root causes matters in cancer prevention and recovery.  Join me and my guest, Sylvie Beljanski, President of The Beljanski Foundation, to learn more about her father's pioneering work in molecular biology, his discovery of plant extracts that selectively target cancer cells, and the remarkable story behind a research legacy that continues today.

Brian Kukan is a treasure. Not only is he doing powerful work to help those with cancer using his reiki, he is a musician and mathematician. I am glad to have him back on the show to demonstrate his skill in numerology.He reads the numerology for the AI model titans and we are left speechless.If cancer has ever impacted you and yours, please donate to the group below.And Brian Kukan does remote reiki sessions, selling gift certificates as well. Find him and all his links below.Brian Kukan's LinksLA Reiki Guy, Brian Kukan's websiteweSPARK orgDonate a reiki session to a cancer patient!Send us Fan MailSupport the showSupport Curious Cat, an independent, human-made podcast!Anxious about AI? Take two minutes to contact your local politician and ask them to tap the brakes on this technology. Still worried? Contact one of the orgs below and get involved. But for today, hug your kid, cook food and really breathe in deep as it simmers, walk in nature, brush a cat, donate to the food bank, brew a cup of tea, or draw a five-minute portrait of your dog. ***Is AI the Devil? on Substack!***Hero Organizations:80,000 HoursCenter for Humane TechnologiesState of Surveillance, an organization that helps foster online privacyBuy Curious Cat Podcast a Coffee!

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, speaks with W. Kimryn Rathmell, MD, PhD, about the new and evolving ways cancer care is delivered, building networks through advocacy and more. ·       Who is Dr. W. Kimryn Rathmell?  2:17 ·       Jain and Rathmell discuss the need for physician scientists in administrative leadership. 11:37 ·       How do you think networks and communities can impact careers? 17:08 ·       What are your thoughts on using social media in the cancer space? 22:35 ·       How do you think AI is going to transform the way we deliver care? 26:21 ·       As you have navigated your career, how have you approached challenges around being a woman in leadership roles? 29:29 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Rathmell can be reached on LinkedIn. Jain reports no relevant financial disclosures. Rathmell reports a relationship with Interact Therapeutics, as well as institution relationships with Merck and Sitryx.